| Bioactivity | MS6105 is an LDH protein hydrolysis-targeted chimera (PROTAC) that effectively degrades LDHA and LDHB in a time- and ubiquitin-proteasome system-dependent manner and has anticancer activity[1]. |
| Invitro | MS6105 (compound 22) (10 nM-10 μM, 48 h) 可以以时间和浓度依赖的方式有效地诱导 PANC1 细胞中 LDHA 和 LDHB 降解，作用于 LDHA 和 LDHB 的 DC50 值分别是 38 和74 nM[1]。 MS6105 (compound 22) (0.1-1 μM, 48 h) 有效抑制 PANC1 细胞增殖，其 GI 50 值为16.1 μM，同时抑制 MiaPaca2 细胞生长的 GI50 值为 12.2 μM[1]。 |
| Name | MS6105 |
| Formula | C65H81N9O9S3 |
| Molar Mass | 1228.59 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Ning Sun, et al. Discovery of the First Lactate Dehydrogenase Proteolysis Targeting Chimera Degrader for the Treatment of Pancreatic Cancer. J Med Chem. 2023 Jan 12;66(1):596-610. |